The Future of Pharmaceutical Engineering

Journal of Pharmaceutical Sciences

Volumn 93, Issue 2, 2004, Pages 235-238

  Mendricks, L ^a   Vanroeyen, J ^a   Wang, H Y ^a  

^a UNIVERSITY OF MICHIGAN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOTECHNOLOGY; DRUG INDUSTRY; DRUG MANUFACTURE; DRUG MARKETING; DRUG RESEARCH; ECONOMIC EVALUATION; EDUCATION; EDUCATION PROGRAM; ENGINEERING; FOOD AND DRUG ADMINISTRATION; GOOD MANUFACTURING PRACTICE; HEALTH CARE INDUSTRY; HIGH THROUGHPUT SCREENING; NOTE; PATENT; PHARMACEUTICAL ENGINEERING; PHARMACOGENOMICS; PHARMACY; POSTGRADUATE EDUCATION; TOTAL QUALITY MANAGEMENT;

EID: 0842332517     PISSN: 00223549     EISSN: None     Source Type: Journal    
DOI: 10.1002/jps.10542     Document Type: Note

References (9)

1. Pharma 2005: Marketing to the individual. IBM Business Consulting Services; 2002.
2. Pharma 2005: An industrial revolution in R&D. IBM Business Consulting Services; 2002.
3. Tufts center pegs cost of a new prescription medicine at $802 million. Tufts Center for the Study of Drug Development; 2001.
4. A revolution in R&D: How genomics and genetics are transforming the biopharmaceutical industry. Boston Consulting Group; 2001.
5. Pharma 2010: The threshold of innovation. IBM Business Consulting Services; 2002.
6. Outlook 2003. Tufts Center for the Study of Drug Development; 2003.
7. Pharma 2005: Silicon rally: The race to e-R&D. IBM Business Consulting Services; 2002.
8. Pharmaceutical cGMPs for the 21st century: A risk-based approach. US Food and Drug Administration. http://www.fda.gov/cder/gmp/index.htm.
9. Process analytical technologies (PAT) initiative. US Food and Drug Administration. Center for Drug Evaluation and Research. http://www.fda.gov/cder/OPS/PAT.htm.